Molecular Predictors of Durable Remission After First-Line Targeted Agents in CLL

Molecular Predictors of Durable Remission After First-Line Targeted Agents in CLL

Blood  

I include this piece because CLL Chronic Lymphocytic Leukemia is the most common chronic leukemia and its incidence increase with age and we are aging  AND because I have been teaching in the book, on FB and on the blog aout genetics of the cancer cells and how they may offer keys to not only prognosis identification- who will do well with what gene or genes or not BUT in the beginning revolutionary techniques are used to see IF there are gene aberrancies in the cancer cells and IF they seem to relate to how one will do . This is a perfect example of beautiful work which did just that. Now they will try to design ways to attack the fact that these aberrancies exist or find out what exactly are those genes a blueprint for and maybe attack that process or product. Is that not elegant?  Dr Ryan

  In this retrospective, multicenter analysis of 404 chronic lymphocytic leukemia (CLL) patients who underwent front-line fludarabine, cyclophosphamide, and rituximab (FCR) therapy, the authors evaluated clinical outcomes with respect to IGHV mutation, 11q deletion, and 17p deletion status as potential risk-stratification biomarkers. Patients with mutated IGHV genes but without 11q or 17p deletions were identified as low-risk for disease relapse or mortality (similar to risk in the general population) compared with their intermediate- (mutated IGHV / 11q deletion) and high-risk (17p deletion) counterparts (median PFS, not-reached vs 51.7 months vs 22.5 months; P < .0001; 5-year OS, 91.4% vs 83.2% vs 57.5%; P = .0004).

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s